Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Trabectedin as a chemotherapy option for patients with BRCA deficiency.

Monk BJ, Lorusso D, Italiano A, Kaye SB, Aracil M, Tanović A, D'Incalci M.

Cancer Treat Rev. 2016 Nov;50:175-182. doi: 10.1016/j.ctrv.2016.09.009. Epub 2016 Sep 15. Review.

PMID:
27710871
2.

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.

Monk BJ, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita AS, Nieto A, Park YC, Cheng PS, Li W, Favis R, Ricci D, Poveda A.

Ann Oncol. 2015 May;26(5):914-20. doi: 10.1093/annonc/mdv071. Epub 2015 Feb 26.

PMID:
25722380
3.

Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.

[No authors listed]

Drugs R D. 2006;7(5):317-28. Review.

PMID:
16922593
4.

Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.

Monk BJ, Dalton H, Benjamin I, Tanović A.

Curr Pharm Des. 2012;18(25):3754-69. Review.

PMID:
22591421
5.
6.

The efficacy of trabectedin in treating ovarian cancer.

Teplinsky E, Herzog TJ.

Expert Opin Pharmacother. 2017 Feb;18(3):313-323. doi: 10.1080/14656566.2017.1285282. Review.

PMID:
28140689
7.

Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.

Lorusso D, Scambia G, Pignata S, Sorio R, Amadio G, Lepori S, Mosconi A, Pisano C, Mangili G, Maltese G, Sabbatini R, Artioli G, Gamucci T, Di Napoli M, Capoluongo E, Ludovini V, Raspagliesi F, Ferrandina G.

Ann Oncol. 2016 Mar;27(3):487-93. doi: 10.1093/annonc/mdv608. Epub 2015 Dec 17.

PMID:
26681678
8.

Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.

Carter NJ, Keam SJ.

Drugs. 2010 Feb 12;70(3):355-76. doi: 10.2165/11202860-000000000-00000. Review.

PMID:
20166769
9.

Unique features of trabectedin mechanism of action.

Larsen AK, Galmarini CM, D'Incalci M.

Cancer Chemother Pharmacol. 2016 Apr;77(4):663-71. doi: 10.1007/s00280-015-2918-1. Epub 2015 Dec 14. Review.

PMID:
26666647
10.

Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.

López-Guerrero JA, Romero I, Poveda A.

Chin J Cancer. 2015 Jan;34(1):41-9. doi: 10.5732/cjc.014.10278. Review.

11.

Trabectedin: Supportive care strategies and safety profile.

Jordan K, Jahn F, Jordan B, Kegel T, Müller-Tidow C, Rüssel J.

Crit Rev Oncol Hematol. 2015 Jun;94(3):279-90. doi: 10.1016/j.critrevonc.2015.02.012. Epub 2015 Mar 6. Review.

PMID:
25794812
12.

Trabectedin mechanism of action and platinum resistance: molecular rationale.

Ray-Coquard I.

Future Oncol. 2017 Oct;13(23s):17-21. doi: 10.2217/fon-2017-0318. Epub 2017 Oct 11. Review.

PMID:
29020822
13.

Trabectedin clinical cases: use according to indication in diverse clinical scenarios.

Grignani G, Martín-Broto J, Schuler M, Reichardt P.

Future Oncol. 2015;11(11 Suppl):15-24. doi: 10.2217/fon.15.76.

PMID:
26043311
14.

Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.

García MJ, Saucedo-Cuevas LP, Muñoz-Repeto I, Fernández V, Robles MJ, Domingo S, Palacios J, Aracil M, Nieto A, Tercero JC, Benítez J.

Mol Cancer Ther. 2013 Apr;12(4):530-41. doi: 10.1158/1535-7163.MCT-12-0768. Epub 2013 Jan 30.

15.

Biology of ovarian cancer and trabectedin mechanism of action.

Ray-Coquard I.

Future Oncol. 2013 Dec;9(12 Suppl):11-7. doi: 10.2217/fon.13.199. Review.

PMID:
24195525
16.

Trabectedin for the management of soft-tissue sarcoma.

Boudou L, Baconnier M, Blay JY, Lombard-Bohas C, Cassier PA.

Expert Rev Anticancer Ther. 2009 Jun;9(6):727-37. doi: 10.1586/era.09.28. Review.

PMID:
19496709
17.

Trabectedin for the treatment of breast cancer.

D'Incalci M, Zambelli A.

Expert Opin Investig Drugs. 2016;25(1):105-15. doi: 10.1517/13543784.2016.1124086. Epub 2015 Dec 22. Review.

PMID:
26592307
18.

Trabectedin and ovarian cancer: statistical trickery.

[No authors listed]

Prescrire Int. 2011 Apr;20(115):93. No abstract available.

PMID:
21648209
19.

Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.

Schöffski P, Taron M, Jimeno J, Grosso F, Sanfilipio R, Casali PG, Le Cesne A, Jones RL, Blay JY, Poveda A, Maki RG, Nieto A, Tercero JC, Rosell R.

Eur J Cancer. 2011 May;47(7):1006-12. doi: 10.1016/j.ejca.2011.01.016. Epub 2011 Mar 4.

PMID:
21376569
20.

Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.

Massuti B, Cobo M, Camps C, Dómine M, Provencio M, Alberola V, Viñolas N, Rosell R, Tarón M, Gutiérrez-Calderón V, Lardelli P, Alfaro V, Nieto A, Isla D.

Lung Cancer. 2012 Jun;76(3):354-61. doi: 10.1016/j.lungcan.2011.12.002. Epub 2011 Dec 23.

PMID:
22197612

Supplemental Content

Support Center